PMID- 28816567
OWN - NLM
STAT- MEDLINE
DCOM- 20180511
LR  - 20220129
IS  - 1744-8352 (Electronic)
IS  - 1473-7159 (Linking)
VI  - 17
IP  - 10
DP  - 2017 Oct
TI  - How close are we to implementing a genetic risk score for coronary heart disease?
PG  - 905-915
LID - 10.1080/14737159.2017.1368388 [doi]
AB  - Genome-wide association meta-analysis have now identified more than 150 loci 
      where common variants (SNPs) are significantly associated with coronary heart 
      disease (CHD) and CHD end points. Areas covered: The authors review publications 
      from their own laboratory and published recently where identified CHD risk SNPs 
      are used in combination, and 'scaled' by their effect size, to create a 
      'weighted' Genetic risk Score (GRS), which, in combination with an individual's 
      classical CHD risk factors, can be used to identify those at overall low, 
      intermediate and high future risk. Those at highest risk can be offered 
      life-style and therapeutic options to reduce their risk and those at intermediate 
      levels can be monitored. Expert commentary: The authors discuss the selection of 
      the best variants to be included in the GRS, and the potential utility of such 
      scores in different clinical settings. The limitations of the current data sets 
      and the way forward in the next 5 years is discussed.
FAU - Beaney, Katherine
AU  - Beaney K
AD  - a Centre for Cardiovascular Genetics, BHF Laboratories, Institute of 
      Cardiovascular Science , University College London , London , UK.
FAU - Drenos, Fotios
AU  - Drenos F
AD  - a Centre for Cardiovascular Genetics, BHF Laboratories, Institute of 
      Cardiovascular Science , University College London , London , UK.
AD  - b MRC Integrative Epidemiology Unit, School of Social and Community Medicine , 
      University of Bristol , Bristol , UK.
FAU - Humphries, Steve E
AU  - Humphries SE
AD  - a Centre for Cardiovascular Genetics, BHF Laboratories, Institute of 
      Cardiovascular Science , University College London , London , UK.
LA  - eng
GR  - RG/08/008/25291/BHF_/British Heart Foundation/United Kingdom
GR  - MC_UU_12013/1-9/MRC_/Medical Research Council/United Kingdom
GR  - 1270920/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170904
PL  - England
TA  - Expert Rev Mol Diagn
JT  - Expert review of molecular diagnostics
JID - 101120777
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Leupeptins)
RN  - 110044-82-1 (acetylleucyl-leucyl-norleucinal)
SB  - IM
MH  - Coronary Disease/*diagnosis/epidemiology/*genetics/prevention & control
MH  - *Genetic Association Studies/methods
MH  - *Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Genome-Wide Association Study/methods
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Leupeptins
MH  - Medication Adherence
MH  - Polymorphism, Single Nucleotide
MH  - Practice Guidelines as Topic
MH  - Primary Prevention/methods
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - United Kingdom/epidemiology
OTO - NOTNLM
OT  - Genome wide association studies
OT  - algorithm
OT  - classical risk factors
OT  - coronary heart disease
OT  - genetic risk score
EDAT- 2017/08/18 06:00
MHDA- 2018/05/12 06:00
CRDT- 2017/08/18 06:00
PHST- 2017/08/18 06:00 [pubmed]
PHST- 2018/05/12 06:00 [medline]
PHST- 2017/08/18 06:00 [entrez]
AID - 10.1080/14737159.2017.1368388 [doi]
PST - ppublish
SO  - Expert Rev Mol Diagn. 2017 Oct;17(10):905-915. doi: 
      10.1080/14737159.2017.1368388. Epub 2017 Sep 4.